CFO Matthew Gall resigns; CAO Brett Hagen takes over as principal financial officer

Kalaris Therapeutics, Inc.

Matthew Gall resigned as CFO, effective April 14, 2026.
Brett Hagen, Chief Accounting Officer since Jan 2019, will serve as principal financial officer.
Hagen previously held finance roles at Eloxx Pharmaceuticals, Proteostasis Therapeutics, and BIND Therapeutics.
No changes to Hagen’s compensatory plans or arrangements were disclosed.
Resignation reason not stated; departure is effective April 14, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.